b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">30927589</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>17</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1090-2120</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>87</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>06</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Bioorganic chemistry</Title>\n                <ISOAbbreviation>Bioorg. Chem.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Synthesis and biological evaluation of new bisindole-imidazopyridine hybrids as apoptosis inducers.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>484-494</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0045-2068(18)30617-5</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioorg.2019.03.061</ELocationID>\n            <Abstract>\n                <AbstractText>A series of diindolylmethanes (5a-t) were designed, synthesized, and examined for their cytotoxicity against four human cancer cell lines like prostate (DU-145), lung (A549), breast (MCF-7) and cervical cancer (HeLa). These results revealed that among all the hybrids, two (5k and 5r) were identified and exhibited significant cytotoxic effect against A549 cancer cells with IC<sub>50</sub> values of 1.65\xe2\x80\xaf\xc2\xb1\xe2\x80\xaf0.3 and 1.80\xe2\x80\xaf\xc2\xb1\xe2\x80\xaf0.8\xe2\x80\xaf\xc2\xb5M respectively. To investigate the reasons for the cytotoxic activity, the conventional biological assays were carried out with 5k and 5r on the A549 cancer cells. Both hybrids led to the arrest of A549 cell lines at the G2/M phase of the cell cycle and strongly induced apoptosis. Further the apoptotic effects of 5k and 5r were confirmed by ROS, annexin-V FITC, and mitochondrial membrane potential. Moreover, structure-activity relationships were elucidated with various substitutions on these hybrids.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Sunkari</LastName>\n                    <ForeName>Satish</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India; Academy of Scientific and Innovative Research, New Delhi 110 025, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bonam</LastName>\n                    <ForeName>Srinivasa Reddy</ForeName>\n                    <Initials>SR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Academy of Scientific and Innovative Research, New Delhi 110 025, India; Vaccine Immunology Laboratory, Natural Product Chemistry Division, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rao</LastName>\n                    <ForeName>A V Subba</ForeName>\n                    <Initials>AVS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Riyaz</LastName>\n                    <ForeName>Sd</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Chemistry, Jawaharlal Nehru Technological University, Hyderabad 500085, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lakshma Nayak</LastName>\n                    <ForeName>V</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kumar</LastName>\n                    <ForeName>Halmuthur Mahabalarao Sampath</ForeName>\n                    <Initials>HMS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Academy of Scientific and Innovative Research, New Delhi 110 025, India; Vaccine Immunology Laboratory, Natural Product Chemistry Division, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kamal</LastName>\n                    <ForeName>Ahmed</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India; Academy of Scientific and Innovative Research, New Delhi 110 025, India; School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi 110062, India. Electronic address: ahmedkamal915@gmail.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nagendra Babu</LastName>\n                    <ForeName>Bathini</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre for Semio Chemicals, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500007, India; Academy of Scientific and Innovative Research, New Delhi 110 025, India. Electronic address: bathini@iict.res.in.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Bioorg Chem</MedlineTA>\n            <NlmUniqueID>1303703</NlmUniqueID>\n            <ISSNLinking>0045-2068</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Apoptosis</Keyword>\n            <Keyword MajorTopicYN="Y">Bisindole-imidazopyridine</Keyword>\n            <Keyword MajorTopicYN="Y">Cytotoxicity</Keyword>\n            <Keyword MajorTopicYN="Y">Heterocyclic</Keyword>\n            <Keyword MajorTopicYN="Y">ROS</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>19</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>21</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30927589</ArticleId>\n            <ArticleId IdType="pii">S0045-2068(18)30617-5</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.bioorg.2019.03.061</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'